Phase II Study of Sacituzumab Govitecan-hziy for Adults With Advanced Thymoma and Thymic Carcinoma After Previous Treatment

What this Trial Is About

This trial studies sacituzumab govitecan-hziy in adults with advanced thymoma and thymic carcinoma who have progressed after at least one prior treatment. The main goal is to find the overall response rate in these patients, which helps understand how the cancer responds to this therapy. The study is a Phase II trial led by Georgetown University focusing on this rare and advanced cancer type. Participants receive sacituzumab govitecan-hziy at a fixed dose of 10 mgkg intravenously once weekly on Days 1 and 8 within 21-day cycles. Treatment continues until the cancer progresses or side effects become unacceptable. This approach allows ongoing monitoring of effects and tolerability over repeated cycles. During the study, participants will have regular blood tests, scans, and physical exams to track health and cancer status. Researchers will collect blood and tumor biopsies for research. They will measure outcomes like overall response rate at one year, duration of response, progression-free survival, and overall survival, with safety closely monitored throughout the treatment period.

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors